Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population

Maren Weischer; Klaus Juul; Jeppe Zacho; Gorm B Jensen; Rolf Steffensen; Torben V Schroeder; Anne Tybjærg-Hansen; Børge G Nordestgaard; Maren Weischer; Klaus Juul; Jeppe Zacho; Gorm B Jensen; Rolf Steffensen; Torben V Schroeder; Anne Tybjaerg-Hansen; Børge G Nordestgaard

doi:10.1016/j.atherosclerosis.2009.05.006

Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population

Maren Weischer, Klaus Juul, Jeppe Zacho, Gorm B Jensen, Rolf Steffensen, Torben V Schroeder, Anne Tybjærg-Hansen, Børge G Nordestgaard, Maren Weischer, Klaus Juul, Jeppe Zacho, Gorm B Jensen, Rolf Steffensen, Torben V Schroeder, Anne Tybjaerg-Hansen, Børge G Nordestgaard

21 Citations (Scopus)

Abstract

Objective: We tested the hypotheses that Prothrombin G20210A heterozygosity associate with increased risk of venous thromboembolism (VTE), ischemic heart disease (IHD), and ischemic cerebrovascular disease (ICVD) in the general population and re-tested risk of IHD and ICVD in two case-control studies. Methods: 9231 individuals from the Danish general population were followed for VTE (VTE = DVT + PE), deep venous thrombosis (DVT), pulmonary embolism (PE), IHD, myocardial infarction (MI), ICVD, and ischemic stroke (IS) for a median of 24 years. Case-control studies included 2461 IHD cases and 867 ICVD cases. Results: In the general population, Prothrombin G20210A heterozygotes had1.3 (95% CI:0.6-2.9) fold risk for VTE, 0.6 (0.2-2.0) for DVT, 1.7(0.6-4.8) for PE, 1.5(1.1-2.1) for IHD, 1.7(1.1-2.7) for MI, 1.1(0.6-1.9) for ICVD, and 1.1(0.5-2.1) for IS compared to non-carriers. Double heterozygotes for Prothrombin G20210A and Factor V Leiden versus double non-carriers had a multifactorially adjusted hazard ratio for IHD of 6.0(2.0-19). In case-control studies, multifactorially adjusted odds ratios for Prothrombin G20210A heterozygotes versus non-carriers were 2.0(1.1-3.4) for IHD, 2.0(1.0-3.8) for MI, 1.4(0.7-3.1) for ICVD, and 2.1(0.8-5.4) for IS. Conclusion: Prothrombin G20210A heterozygosity alone and in combination with Factor V Leiden R506Q heterozygosity predicts 1.5 and 6.0 fold risk of IHD compared to non-carriers.

Original language	English
Journal	Atherosclerosis
Volume	208
Issue number	2
Pages (from-to)	480-3
Number of pages	4
ISSN	0021-9150
DOIs	https://doi.org/10.1016/j.atherosclerosis.2009.05.006
Publication status	Published - 1 Feb 2010

Access to Document

10.1016/j.atherosclerosis.2009.05.006

Cite this

Weischer, M., Juul, K., Zacho, J., Jensen, G. B., Steffensen, R., Schroeder, T. V., Tybjærg-Hansen, A., Nordestgaard, B. G., Weischer, M., Juul, K., Zacho, J., Jensen, G. B., Steffensen, R., Schroeder, T. V., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2010). Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population. Atherosclerosis, 208(2), 480-3. https://doi.org/10.1016/j.atherosclerosis.2009.05.006

Weischer, M, Juul, K, Zacho, J, Jensen, GB, Steffensen, R, Schroeder, TV, Tybjærg-Hansen, A, Nordestgaard, BG, Weischer, M, Juul, K, Zacho, J, Jensen, GB, Steffensen, R, Schroeder, TV, Tybjaerg-Hansen, A & Nordestgaard, BG 2010, 'Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population', Atherosclerosis, vol. 208, no. 2, pp. 480-3. https://doi.org/10.1016/j.atherosclerosis.2009.05.006

@article{fff8a0f0ff5911de825d000ea68e967b,

title = "Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population",

abstract = "Objective: We tested the hypotheses that Prothrombin G20210A heterozygosity associate with increased risk of venous thromboembolism (VTE), ischemic heart disease (IHD), and ischemic cerebrovascular disease (ICVD) in the general population and re-tested risk of IHD and ICVD in two case-control studies. Methods: 9231 individuals from the Danish general population were followed for VTE (VTE = DVT + PE), deep venous thrombosis (DVT), pulmonary embolism (PE), IHD, myocardial infarction (MI), ICVD, and ischemic stroke (IS) for a median of 24 years. Case-control studies included 2461 IHD cases and 867 ICVD cases. Results: In the general population, Prothrombin G20210A heterozygotes had1.3 (95% CI:0.6-2.9) fold risk for VTE, 0.6 (0.2-2.0) for DVT, 1.7(0.6-4.8) for PE, 1.5(1.1-2.1) for IHD, 1.7(1.1-2.7) for MI, 1.1(0.6-1.9) for ICVD, and 1.1(0.5-2.1) for IS compared to non-carriers. Double heterozygotes for Prothrombin G20210A and Factor V Leiden versus double non-carriers had a multifactorially adjusted hazard ratio for IHD of 6.0(2.0-19). In case-control studies, multifactorially adjusted odds ratios for Prothrombin G20210A heterozygotes versus non-carriers were 2.0(1.1-3.4) for IHD, 2.0(1.0-3.8) for MI, 1.4(0.7-3.1) for ICVD, and 2.1(0.8-5.4) for IS. Conclusion: Prothrombin G20210A heterozygosity alone and in combination with Factor V Leiden R506Q heterozygosity predicts 1.5 and 6.0 fold risk of IHD compared to non-carriers.",

author = "Maren Weischer and Klaus Juul and Jeppe Zacho and Jensen, {Gorm B} and Rolf Steffensen and Schroeder, {Torben V} and Anne Tybj{\ae}rg-Hansen and Nordestgaard, {B{\o}rge G} and Maren Weischer and Klaus Juul and Jeppe Zacho and Jensen, {Gorm B} and Rolf Steffensen and Schroeder, {Torben V} and Anne Tybjaerg-Hansen and Nordestgaard, {B{\o}rge G}",

year = "2010",

month = feb,

day = "1",

doi = "10.1016/j.atherosclerosis.2009.05.006",

language = "English",

volume = "208",

pages = "480--3",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population

AU - Weischer, Maren

AU - Juul, Klaus

AU - Zacho, Jeppe

AU - Jensen, Gorm B

AU - Steffensen, Rolf

AU - Schroeder, Torben V

AU - Tybjærg-Hansen, Anne

AU - Nordestgaard, Børge G

AU - Weischer, Maren

AU - Juul, Klaus

AU - Zacho, Jeppe

AU - Jensen, Gorm B

AU - Steffensen, Rolf

AU - Schroeder, Torben V

AU - Tybjaerg-Hansen, Anne

AU - Nordestgaard, Børge G

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Objective: We tested the hypotheses that Prothrombin G20210A heterozygosity associate with increased risk of venous thromboembolism (VTE), ischemic heart disease (IHD), and ischemic cerebrovascular disease (ICVD) in the general population and re-tested risk of IHD and ICVD in two case-control studies. Methods: 9231 individuals from the Danish general population were followed for VTE (VTE = DVT + PE), deep venous thrombosis (DVT), pulmonary embolism (PE), IHD, myocardial infarction (MI), ICVD, and ischemic stroke (IS) for a median of 24 years. Case-control studies included 2461 IHD cases and 867 ICVD cases. Results: In the general population, Prothrombin G20210A heterozygotes had1.3 (95% CI:0.6-2.9) fold risk for VTE, 0.6 (0.2-2.0) for DVT, 1.7(0.6-4.8) for PE, 1.5(1.1-2.1) for IHD, 1.7(1.1-2.7) for MI, 1.1(0.6-1.9) for ICVD, and 1.1(0.5-2.1) for IS compared to non-carriers. Double heterozygotes for Prothrombin G20210A and Factor V Leiden versus double non-carriers had a multifactorially adjusted hazard ratio for IHD of 6.0(2.0-19). In case-control studies, multifactorially adjusted odds ratios for Prothrombin G20210A heterozygotes versus non-carriers were 2.0(1.1-3.4) for IHD, 2.0(1.0-3.8) for MI, 1.4(0.7-3.1) for ICVD, and 2.1(0.8-5.4) for IS. Conclusion: Prothrombin G20210A heterozygosity alone and in combination with Factor V Leiden R506Q heterozygosity predicts 1.5 and 6.0 fold risk of IHD compared to non-carriers.

AB - Objective: We tested the hypotheses that Prothrombin G20210A heterozygosity associate with increased risk of venous thromboembolism (VTE), ischemic heart disease (IHD), and ischemic cerebrovascular disease (ICVD) in the general population and re-tested risk of IHD and ICVD in two case-control studies. Methods: 9231 individuals from the Danish general population were followed for VTE (VTE = DVT + PE), deep venous thrombosis (DVT), pulmonary embolism (PE), IHD, myocardial infarction (MI), ICVD, and ischemic stroke (IS) for a median of 24 years. Case-control studies included 2461 IHD cases and 867 ICVD cases. Results: In the general population, Prothrombin G20210A heterozygotes had1.3 (95% CI:0.6-2.9) fold risk for VTE, 0.6 (0.2-2.0) for DVT, 1.7(0.6-4.8) for PE, 1.5(1.1-2.1) for IHD, 1.7(1.1-2.7) for MI, 1.1(0.6-1.9) for ICVD, and 1.1(0.5-2.1) for IS compared to non-carriers. Double heterozygotes for Prothrombin G20210A and Factor V Leiden versus double non-carriers had a multifactorially adjusted hazard ratio for IHD of 6.0(2.0-19). In case-control studies, multifactorially adjusted odds ratios for Prothrombin G20210A heterozygotes versus non-carriers were 2.0(1.1-3.4) for IHD, 2.0(1.0-3.8) for MI, 1.4(0.7-3.1) for ICVD, and 2.1(0.8-5.4) for IS. Conclusion: Prothrombin G20210A heterozygosity alone and in combination with Factor V Leiden R506Q heterozygosity predicts 1.5 and 6.0 fold risk of IHD compared to non-carriers.

U2 - 10.1016/j.atherosclerosis.2009.05.006

DO - 10.1016/j.atherosclerosis.2009.05.006

M3 - Journal article

C2 - 19524925

SN - 0021-9150

VL - 208

SP - 480

EP - 483

JO - Atherosclerosis

JF - Atherosclerosis

IS - 2

ER -

Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population

Abstract

Access to Document

Fingerprint

Cite this